Adaptive Biotechnologies Corporation (ADPT) Stock Grade

About Adaptive Biotechnologies Corporation's fundamentals

Adaptive Biotechnologies is a biotechnology company with a market capitalization of $2.5 billion that demonstrated strong revenue growth of 54.8% year-over-year. However, the company is currently unprofitable, with a net margin of -21.5% and reported a net loss in its latest annual statement, meaning it is spending more than it generates in revenue. The company does not pay a dividend. As a pre-profitability biotech firm, Adaptive Biotechnologies is in a growth phase where it is investing heavily in development and operations ahead of generating positive earnings.